ELEKTA'S BOARD DECIDES ON REPURCHASE OF OWN SHARES

ELEKTA'S BOARD DECIDES ON REPURCHASE OF OWN SHARES

PRESS RELEASE			
Stockholm, Sweden, July 2, 2007 

The Board of Directors of Elekta AB (publ) has decided to utilize the
authorization the Board received from the Annual General Meeting to repurchase
shares in the company.

Elekta's distribution policy is to distribute 20 percent or more of net profit
to shareholders in the form of dividends, share repurchases or comparable
measures. Elekta's Annual General Meeting on September 20, 2006 resolved to
authorize the Board to decide on the acquisition of a maximum of 10 percent of
the total number of shares in the company.

The Board today decided to exercise the mandate to authorize the executive
management to initiate, on appropriate occasions, the repurchase of shares in an
amount of SEK 100 M, but maximized to 1,000,000 shares.

As of today Elekta own 759,271 of its own shares. A repurchase of 1,000,000
shares is corresponding to 1.1 percent of the total number of outstanding shares
in the company. Elekta intends to propose to the AGM that repurchased shares
will be cancelled. 

Purchases will be made on the Nordic Exchange and to a price within the spread
at the time of purchase. Purchases can be made during the time until next Annual
General Meeting.


********

For further information, please contact:

Okee Williams 
Corporate Communications, Elekta AB 
Tel: +46 70 600 53 64 (mobile), e-mail: okee.williams@elekta.com 

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders.  
With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. For more information about Elekta, please visit www.elekta.com.